Lumos Pharma, Inc. Expected to Post Q4 2023 Earnings of ($0.87) Per Share (NASDAQ:LUMO)

Lumos Pharma, Inc. (NASDAQ:LUMOGet Rating) – Stock analysts at Jefferies Financial Group issued their Q4 2023 earnings per share estimates for shares of Lumos Pharma in a research report issued to clients and investors on Wednesday, March 1st. Jefferies Financial Group analyst E. Yang forecasts that the company will post earnings per share of ($0.87) for the quarter. Jefferies Financial Group currently has a “Hold” rating on the stock. The consensus estimate for Lumos Pharma’s current full-year earnings is ($3.75) per share. Jefferies Financial Group also issued estimates for Lumos Pharma’s FY2027 earnings at ($1.09) EPS.

Several other equities analysts have also recently issued reports on LUMO. Cantor Fitzgerald reiterated an “overweight” rating on shares of Lumos Pharma in a research note on Tuesday, November 15th. Oppenheimer cut their target price on Lumos Pharma to $18.00 in a research report on Thursday, November 17th.

Lumos Pharma Stock Performance

Shares of LUMO opened at $3.49 on Friday. The stock has a 50-day simple moving average of $3.55 and a 200-day simple moving average of $6.08. The stock has a market capitalization of $29.32 million, a PE ratio of -0.94 and a beta of 0.99. Lumos Pharma has a 1 year low of $2.95 and a 1 year high of $10.17.

Institutional Investors Weigh In On Lumos Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in shares of Lumos Pharma during the 4th quarter worth about $38,000. Shay Capital LLC acquired a new position in Lumos Pharma during the fourth quarter worth approximately $180,000. Millennium Management LLC acquired a new position in Lumos Pharma during the fourth quarter worth approximately $72,000. Jefferies Financial Group Inc. acquired a new position in Lumos Pharma during the fourth quarter worth approximately $436,000. Finally, Envestnet Asset Management Inc. acquired a new position in Lumos Pharma during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 30.53% of the company’s stock.

Lumos Pharma Company Profile

(Get Rating)

Lumos Pharma, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

See Also

Earnings History and Estimates for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.